For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development expenses | 7,810,337 | |||
| General and administrative expenses | 6,178,168 | |||
| Operating loss | -13,988,505 | |||
| Other income | 20,000 | |||
| Unrealized gain on digital assets at fair value | 295,180 | |||
| Interest and dividend income, net | 109,491 | |||
| Net operating loss before income tax benefit | -13,563,834 | |||
| Net loss | -13,563,834 | |||
| Basic EPS | -10.36 | |||
| Diluted EPS | -10.36 | |||
| Basic Average Shares | 1,309,271 | |||
| Diluted Average Shares | 1,309,271 | |||
Processa Pharmaceuticals, Inc. (PCSA)
Processa Pharmaceuticals, Inc. (PCSA)